Retinal effects of 6 months of daily use of tadalafil or sildenafil

William H. Cordell, Raj K. Maturi, Timothy M. Costigan, Michael F. Marmor, Richard Weleber, Stuart G. Coupland, Ronald P. Danis, John W. McGettigan, Andrew N. Antoszyk, Suzanne Klise, Gregory D. Sides

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Objective: To assess changes in electroretinography (ERG) and other retinal function parameters during 6 months of daily use of tadalafil, sildenafil citrate, or placebo. Methods: Subjects were randomized to use of a placebo (n = 82), 5 mg of tadalafil (n = 85), or 50 mg of sildenafil (n = 77) daily for 6 months. Electroretinographs were recorded using the International Society for Clinical Elec- trophysiology of Vision (ISCEV) protocol and standardized ERG equipment at all 15 study sites. Other tests of ocular anatomy and visual function were performed at each assessment. Main Outcome Measures: The primary outcome was the average mean change for both eyes from baseline to endpoint in ERG b-wave amplitude using dark-adapted combined standard response to a bright ISCEV standard flash. Secondary endpoints were other ERG parameter changes, visual acuity, number of errors in color discrimination testing, mean deviation in automated visual field testing, and intraocular pressure (IOP). Results: No significant differences were found between treatment/placebo groups for the primary outcome, most other ERG variables, visual function, IOP, or anatomic assessments. The medications were well tolerated. Conclusions: No abnormalities in ERG or visual function and no treatment-related findings suggestive of drug toxicity are associated with daily administration of tad- alafil or sildenafil for 6 months.

Original languageEnglish (US)
Pages (from-to)367-373
Number of pages7
JournalArchives of Ophthalmology
Volume127
Issue number4
DOIs
StatePublished - Apr 2009

Fingerprint

Electroretinography
Electrophysiology
Placebos
Intraocular Pressure
Drug-Related Side Effects and Adverse Reactions
Visual Fields
Visual Acuity
Sildenafil Citrate
Tadalafil
Anatomy
Color
Outcome Assessment (Health Care)
Equipment and Supplies
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Cordell, W. H., Maturi, R. K., Costigan, T. M., Marmor, M. F., Weleber, R., Coupland, S. G., ... Sides, G. D. (2009). Retinal effects of 6 months of daily use of tadalafil or sildenafil. Archives of Ophthalmology, 127(4), 367-373. https://doi.org/10.1001/archophthalmol.2009.36

Retinal effects of 6 months of daily use of tadalafil or sildenafil. / Cordell, William H.; Maturi, Raj K.; Costigan, Timothy M.; Marmor, Michael F.; Weleber, Richard; Coupland, Stuart G.; Danis, Ronald P.; McGettigan, John W.; Antoszyk, Andrew N.; Klise, Suzanne; Sides, Gregory D.

In: Archives of Ophthalmology, Vol. 127, No. 4, 04.2009, p. 367-373.

Research output: Contribution to journalArticle

Cordell, WH, Maturi, RK, Costigan, TM, Marmor, MF, Weleber, R, Coupland, SG, Danis, RP, McGettigan, JW, Antoszyk, AN, Klise, S & Sides, GD 2009, 'Retinal effects of 6 months of daily use of tadalafil or sildenafil', Archives of Ophthalmology, vol. 127, no. 4, pp. 367-373. https://doi.org/10.1001/archophthalmol.2009.36
Cordell, William H. ; Maturi, Raj K. ; Costigan, Timothy M. ; Marmor, Michael F. ; Weleber, Richard ; Coupland, Stuart G. ; Danis, Ronald P. ; McGettigan, John W. ; Antoszyk, Andrew N. ; Klise, Suzanne ; Sides, Gregory D. / Retinal effects of 6 months of daily use of tadalafil or sildenafil. In: Archives of Ophthalmology. 2009 ; Vol. 127, No. 4. pp. 367-373.
@article{38d757f694a54b6f90ab2b86c535f87b,
title = "Retinal effects of 6 months of daily use of tadalafil or sildenafil",
abstract = "Objective: To assess changes in electroretinography (ERG) and other retinal function parameters during 6 months of daily use of tadalafil, sildenafil citrate, or placebo. Methods: Subjects were randomized to use of a placebo (n = 82), 5 mg of tadalafil (n = 85), or 50 mg of sildenafil (n = 77) daily for 6 months. Electroretinographs were recorded using the International Society for Clinical Elec- trophysiology of Vision (ISCEV) protocol and standardized ERG equipment at all 15 study sites. Other tests of ocular anatomy and visual function were performed at each assessment. Main Outcome Measures: The primary outcome was the average mean change for both eyes from baseline to endpoint in ERG b-wave amplitude using dark-adapted combined standard response to a bright ISCEV standard flash. Secondary endpoints were other ERG parameter changes, visual acuity, number of errors in color discrimination testing, mean deviation in automated visual field testing, and intraocular pressure (IOP). Results: No significant differences were found between treatment/placebo groups for the primary outcome, most other ERG variables, visual function, IOP, or anatomic assessments. The medications were well tolerated. Conclusions: No abnormalities in ERG or visual function and no treatment-related findings suggestive of drug toxicity are associated with daily administration of tad- alafil or sildenafil for 6 months.",
author = "Cordell, {William H.} and Maturi, {Raj K.} and Costigan, {Timothy M.} and Marmor, {Michael F.} and Richard Weleber and Coupland, {Stuart G.} and Danis, {Ronald P.} and McGettigan, {John W.} and Antoszyk, {Andrew N.} and Suzanne Klise and Sides, {Gregory D.}",
year = "2009",
month = "4",
doi = "10.1001/archophthalmol.2009.36",
language = "English (US)",
volume = "127",
pages = "367--373",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - Retinal effects of 6 months of daily use of tadalafil or sildenafil

AU - Cordell, William H.

AU - Maturi, Raj K.

AU - Costigan, Timothy M.

AU - Marmor, Michael F.

AU - Weleber, Richard

AU - Coupland, Stuart G.

AU - Danis, Ronald P.

AU - McGettigan, John W.

AU - Antoszyk, Andrew N.

AU - Klise, Suzanne

AU - Sides, Gregory D.

PY - 2009/4

Y1 - 2009/4

N2 - Objective: To assess changes in electroretinography (ERG) and other retinal function parameters during 6 months of daily use of tadalafil, sildenafil citrate, or placebo. Methods: Subjects were randomized to use of a placebo (n = 82), 5 mg of tadalafil (n = 85), or 50 mg of sildenafil (n = 77) daily for 6 months. Electroretinographs were recorded using the International Society for Clinical Elec- trophysiology of Vision (ISCEV) protocol and standardized ERG equipment at all 15 study sites. Other tests of ocular anatomy and visual function were performed at each assessment. Main Outcome Measures: The primary outcome was the average mean change for both eyes from baseline to endpoint in ERG b-wave amplitude using dark-adapted combined standard response to a bright ISCEV standard flash. Secondary endpoints were other ERG parameter changes, visual acuity, number of errors in color discrimination testing, mean deviation in automated visual field testing, and intraocular pressure (IOP). Results: No significant differences were found between treatment/placebo groups for the primary outcome, most other ERG variables, visual function, IOP, or anatomic assessments. The medications were well tolerated. Conclusions: No abnormalities in ERG or visual function and no treatment-related findings suggestive of drug toxicity are associated with daily administration of tad- alafil or sildenafil for 6 months.

AB - Objective: To assess changes in electroretinography (ERG) and other retinal function parameters during 6 months of daily use of tadalafil, sildenafil citrate, or placebo. Methods: Subjects were randomized to use of a placebo (n = 82), 5 mg of tadalafil (n = 85), or 50 mg of sildenafil (n = 77) daily for 6 months. Electroretinographs were recorded using the International Society for Clinical Elec- trophysiology of Vision (ISCEV) protocol and standardized ERG equipment at all 15 study sites. Other tests of ocular anatomy and visual function were performed at each assessment. Main Outcome Measures: The primary outcome was the average mean change for both eyes from baseline to endpoint in ERG b-wave amplitude using dark-adapted combined standard response to a bright ISCEV standard flash. Secondary endpoints were other ERG parameter changes, visual acuity, number of errors in color discrimination testing, mean deviation in automated visual field testing, and intraocular pressure (IOP). Results: No significant differences were found between treatment/placebo groups for the primary outcome, most other ERG variables, visual function, IOP, or anatomic assessments. The medications were well tolerated. Conclusions: No abnormalities in ERG or visual function and no treatment-related findings suggestive of drug toxicity are associated with daily administration of tad- alafil or sildenafil for 6 months.

UR - http://www.scopus.com/inward/record.url?scp=65249111130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249111130&partnerID=8YFLogxK

U2 - 10.1001/archophthalmol.2009.36

DO - 10.1001/archophthalmol.2009.36

M3 - Article

VL - 127

SP - 367

EP - 373

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 4

ER -